Recent Updates
Recently added Catalysts

Raludotatug Deruxtecan

Phase 2

Carcinoma, Non-Small-Cell Lung | Monoclonal antibody | Oncology |Merck & Company, Inc.|Last Updated: Sep 2, 2026

Target and mechanism

ModalityMonoclonal antibody

Also known as Raludotatug Deruxtecan (R-DXd)

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment96

FDA Designations

No designations recorded

Clinical trial landscape

Raludotatug Deruxtecan · 4 trials · 5 indications

Phase 2 3Phase 1 1
NCT06780085A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)Carcinoma, Non-Small-Cell Lung
RECRUITING96 Analytics
NCT06864169A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)Gastrointestinal Cancer
ACTIVE NOT_RECRUITING160 Analytics
NCT06660654A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)Advanced Solid Tumor
ACTIVE NOT_RECRUITING200 Analytics
PHASE2RECRUITING
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Carcinoma, Non-Small-Cell LungUnlock trial analytics
PHASE2ACTIVE NOT_RECRUITING
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
Gastrointestinal CancerUnlock trial analytics
PHASE2ACTIVE NOT_RECRUITING
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
Advanced Solid TumorUnlock trial analytics

Study Endpoints

Primary Endpoints

Objective Response Rate (ORR)
Up to approximately 81 months

ORR is defined as the percentage of participants with Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

Percentage of Participants with at Least One Adverse Event (AE)
Up to approximately 81 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The percentage of participants who experience an AE will be reported.

Percentage of Participants Who Discontinued Medication Due to an AE
Up to approximately 24 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The percentage of participants who discontinue study intervention due to an AE will be reported.

Objective Response Rate as Assessed by the Investigator (All Cohorts Except ccRCC)
Baseline up to 32 months

Objective response rate (ORR) is defined as the proportion of participants with a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST version 1.1 criteria.

Disease Control Rate (DCR) as Assessed by the Investigator (ccRCC Cohort Only)
Baseline up to 32 months

Disease control rate (DCR) is defined as proportion of participants who achieved a BOR of confirmed CR, confirmed PR, or stable disease (maintained for ≥5 weeks) according to RECIST version 1.1.

Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs) (All Cohorts)
Baseline up to 32 months
Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0)
Up to 21 days

DLTs are defined as toxicities during the DLT evaluation period that are assessed by the investigator to be possibly, probably, or definitely related to study treatment and include: Grade 4 thrombocytopenia of any duration or Grade 3 thrombocytopenia lasting ≥7 days; Grade 3 or higher thrombocytopenia associated with clinically significant bleeding; Grade 4 lymphocytopenia lasting ≥14 days; Grade 4 anemia of any duration; any other Grade 4 hematologic toxicity lasting ≥7 days; febrile neutropenia Grade 3 or Grade 4 meeting pre-specifications; pre-specified hepatic organ toxicities; all Grade 3 or higher other nonhematologic toxicities except those pre-specified; other pre-specified nonhematologic toxicities; any delay in treatment with the planned dose of ≥21 days or discontinuation of treatment due to a toxicity during the DLT evaluation period, or Grade 5 toxicity. The number of participants with DLTs will be reported.

Part 1: Number of Participants with One or More Adverse Events (AEs)
Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with one or more AEs will be reported.

Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

Part 2: Objective Response Rate (ORR)
Up to approximately 3 years

ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

Part 2: Progression Free Survival (PFS) - Cohort C-2 Arm 1 and Arm 2
Up to approximately 3 years

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.

Secondary Endpoints

Duration of Response (DOR)
Up to approximately 81 months
Progression-free Survival (PFS)
Up to approximately 81 months
Overall Survival (OS)
Up to approximately 81 months
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Raludotatug DeruxtecanEXPERIMENTALParticipants receive raludotatug deruxtecan (R-DXd) 5.6 mg/kg via intravenous (IV) Infusion every 3 weeks (q3w) until disease progression or discontinuation criterion is met.
Ifinatamab DeruxtecanEXPERIMENTALParticipants receive ifinatamab deruxtecan (I-DXd) 12 mg/kg via IV infusion q3w until disease progression or discontinuation criterion is met.
DocetetaxelACTIVE_COMPARATORParticipants receive docetaxel 75mg/m2 via IV infusion q3w until disease progression or discontinuation criterion is met.
Raludotatug Deruxtecan (R-DXd)EXPERIMENTALR-DXd will be administered via IV infusion.
Endometrial Cancer CohortEXPERIMENTALParticipants with endometrial cancer who will receive raludotatug deruxtecan (R-DXd) administered intravenously every 3 weeks (Q3W).
Cervical Cancer CohortEXPERIMENTALParticipants with cervical cancer who will receive R-DXd administered intravenously Q3W.
Non-high-grade Serous Ovarian CancerEXPERIMENTALParticipants with non-high-grade serous ovarian cancer who will receive R-DXd administered intravenously Q3W.
Urothelial Cancer CohortEXPERIMENTALParticipants with urothelial cancer who will receive R-DXd administered intravenously Q3W.
Clear Cell Renal Carcinoma (ccRCC) CohortEXPERIMENTALParticipants with clear cell renal carcinoma (ccRCC) who will receive R-DXd administered intravenously Q3W.
Cohort A-1 Arm 1 (R-DXd + Carboplatin Dose 1)EXPERIMENTALParticipants receive escalating doses of intravenous (IV) raludotatug deruxtecan (R-DXd) in combination with carboplatin at Dose 1. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive raludotatug deruxtecan until disease progression or discontinuation.
Cohort A-1 Arm 2 (R-DXd + Paclitaxel)EXPERIMENTALParticipants receive escalating doses of IV R-DXd in combination with paclitaxel. Participants can receive up to a maximum of six 3-week cycles of paclitaxel (approximately 4 months) and will receive R-DXd until disease progression or discontinuation.
Cohort A-1 Arm 3 (R-DXd + Carboplatin Dose 2)EXPERIMENTALParticipants receive escalating doses of intravenous (IV) R-DXd in combination with carboplatin at Dose 2. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive R-DXd until disease progression or discontinuation.
Cohort B-1 (R-DXd + Bevacizumab)EXPERIMENTALParticipants receive escalating doses of IV R-DXd in combination with bevacizumab until disease progression or discontinuation.
Cohort B-2 (R-DXd RP2D + Bevacizumab)EXPERIMENTALParticipants with platinum-resistant recurrent ovarian cancer (PRROC) receive recommended Phase 2 dose (RP2D) of IV R-DXd in combination with bevacizumab until disease progression or discontinuation.
Cohort C-1 (R-DXd + Pembrolizumab)EXPERIMENTALParticipants receive escalating doses of IV R-DXd in combination with pembrolizumab. Participants can receive up to a maximum of thirty-five 3-week cycles of pembrolizumab (approximately 2 years) and will receive R-DXd until disease progression or discontinuation.
Cohort D (R-DXd +/- Bevacizumab)EXPERIMENTALParticipants with platinum-sensitive recurrent ovarian cancer (PSROC) receive IV R-DXd in combination with or without bevacizumab until disease progression or discontinuation.
Cohort A-2 Arm 1 (R-DXd RP2D + Carboplatin +/- Bevacizumab)EXPERIMENTALParticipants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of carboplatin with or without bevacizumab, until disease progression or discontinuation.
Cohort A-2 Arm 2 (R-DXd RP2D + Paclitaxel +/- Bevacizumab)EXPERIMENTALParticipants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of paclitaxel with or without bevacizumab, until disease progression or discontinuation.
Cohort A-2 Arm 3 (Platinum-Based Doublet Chemotherapy +/- Bevacizumab)ACTIVE_COMPARATORParticipants with PSROC will receive one of 3 regimens of investigator's choice of platinum-based doublet chemotherapy with or without bevacizumab. Platinum-based doublet chemotherapy will be administered for maximum of 8 cycles. Bevacizumab can be administered until disease progression or discontinuation.
Cohort E-1 (R-DXd + MK-2010)EXPERIMENTALParticipants receive escalating doses of IV R-DXd in combination with MK-2010. Participants can receive up to a maximum of thirty-five 3-week cycles of MK-2010 (approximately 2 years) and will receive R-DXd until disease progression or discontinuation.
Cohort C-2 Arm 1 (Carboplatin + Paclitaxel + Pembrolizumab → R-DXd + Pembrolizumab)EXPERIMENTALParticipants will receive carboplatin (Dose 1 or Dose 2), paclitaxel (five 3-week cycles), and pembrolizumab during the induction phase. During the maintenance phase, participants will receive RP2D of IV R-DXd (up to 2 years; participants with PR or SD at 2 years may continue until disease progression) in combination with pembrolizumab (up to thirty-five 3-week cycles).
Cohort C-2 Arm 2 (Carboplatin + Paclitaxel)EXPERIMENTALParticipants will receive carboplatin (Dose 1 or Dose 2) and paclitaxel (seven 3-week cycles), followed by standard of care observation.
Cohort C-2 Arm 3 (R-DXd + Pembrolizumab + Bevacizumab)EXPERIMENTALParticipants with PSROC will receive RP2D of R-DXd in combination with pembrolizumab (up to thirty-five 3-week cycles) and bevacizumab until progressive disease.

Interventions

NameTypeDescription
Raludotatug DeruxtecanBIOLOGICALIV Infusion
Ifinatamab DeruxtecanBIOLOGICALIV Infusion
DocetetaxelDRUGIV Infusion
5-hydroxytryptamine subtype 3 receptor antagonistDRUGAdministered as a rescue medication per approved product label before R-DXd or I-DXd infusion
Neurokinin-1 receptor antagonistDRUGAdministered as a rescue medication per approved product label before R-DXd or I-DXd infusion
CorticosteroidDRUGAdministered as a rescue medication per approved product label before R-DXd or I-DXd infusion, and for 3 days starting 1 day prior to docetaxel administration
Raludotatug Deruxtecan (R-DXd)BIOLOGICALAdministered via intravenous (IV) infusion.
CarboplatinDRUGIV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.
PaclitaxelDRUGIV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.
BevacizumabBIOLOGICALIV infusion on Day 1 of every 3-week cycle.
Rescue MedicationDRUGIncludes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.
PembrolizumabBIOLOGICALIV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.
GemcitabineDRUGIV injection on days 1 and 8 of each 3-week Cycle
Pegylated liposomal doxorubicinDRUGIV injection administered on Day 1 of each 4-week cycle
MK-2010DRUGIV infusion on Day 1 of every 3-week cycle
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites34

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Histologically or cytologically confirmed diagnosis of Stage IV nonsquamous non-small cell lung cancer (NSCLC) * Documented disease progression per RECIST 1.1 after receiving an anti-programmed cell dea...

Countries:United StatesChileGermanyGreeceHungaryIsraelItalyPolandSpainTurkey (Türkiye)ArgentinaCanadaFranceHong KongSwitzerlandTaiwanThailandBelgiumChinaDenmarkJapanSouth KoreaUnited Kingdom
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMSep 2, 2026NCT06843447Enrollment: 460 → 605
MEDIUMSep 2, 2026NCT06843447Enrollment: 460 → 605
MEDIUMSep 2, 2026NCT06843447Enrollment: 460 → 605
LOWAug 25, 2026NCT06780085lastUpdatePostDate: changed
LOWAug 25, 2026NCT06780085lastUpdatePostDate: changed
LOWAug 14, 2026NCT06843447lastUpdatePostDate: changed
LOWAug 14, 2026NCT06843447lastUpdatePostDate: changed
LOWJul 27, 2026NCT06843447lastUpdatePostDate: changed
LOWJul 27, 2026NCT06843447lastUpdatePostDate: changed
LOWJul 27, 2026NCT06843447lastUpdatePostDate: changed
LOWJul 17, 2026NCT06843447lastUpdatePostDate: changed
LOWJul 17, 2026NCT06843447lastUpdatePostDate: changed
LOWJul 13, 2026NCT06843447lastUpdatePostDate: changed
LOWJul 13, 2026NCT06843447lastUpdatePostDate: changed
LOWJul 6, 2026NCT06780085lastUpdatePostDate: changed
LOWJul 6, 2026NCT06780085lastUpdatePostDate: changed
LOWJun 26, 2026NCT06843447lastUpdatePostDate: changed

Frequently asked questions about Raludotatug Deruxtecan

What is Raludotatug Deruxtecan used for?

Raludotatug Deruxtecan is an investigational monoclonal antibody being studied for advanced solid tumors, gastrointestinal cancer, carcinoma, non-small-cell lung cancer, and recurrent ovarian cancer. It is in Phase 2 clinical development and is not yet approved by the FDA.

What does Raludotatug Deruxtecan target?

Raludotatug Deruxtecan is a monoclonal antibody, but its specific molecular target has not been disclosed in the available information. It is being evaluated across multiple oncology indications, including solid tumors and gastrointestinal cancers.

Who makes Raludotatug Deruxtecan?

Raludotatug Deruxtecan is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in various cancer types.

What phase is Raludotatug Deruxtecan in?

Raludotatug Deruxtecan is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. Multiple trials are ongoing, including a Phase 1 study in ovarian cancer and Phase 2 studies in solid tumors, lung cancer, and gastrointestinal cancers.

What clinical trials is Raludotatug Deruxtecan in?

Raludotatug Deruxtecan is being studied in several trials: NCT06660654 (Phase 2, advanced solid tumors), NCT06780085 (Phase 2, non-small cell lung cancer), NCT06843447 (Phase 1, recurrent ovarian cancer), and NCT06864169 (Phase 2, gastrointestinal cancers). These trials are active and recruiting or not yet recruiting participants.

Is Raludotatug Deruxtecan the same as R-DXd?

Yes, Raludotatug Deruxtecan is also known as R-DXd. This alternative name is used in clinical trial titles and publications, such as the study of R-DXd in people with gastrointestinal cancers (NCT06864169).